Vitroscan's predictive tumor testing service is designed to help oncologists identify the most effective treatments for ovarian cancer patients, addressing a critical need in cancer care.
Ovarian cancer is the most lethal of gynecological cancers, with five-year survival rates below 50% and a relapse rate of 70% within three years. ChemoPredict™ provides vital insights into how tumors respond to chemotherapy, enabling doctors to make personalized treatment decisions and reduce unnecessary side effects for patients.
Biotech Booster's funding will allow VitroScan to build on its partnerships with leading clinical experts from Leiden University Medical Center (LUMC) and Radboud University Medical Center (Radboudumc). These collaborations are essential in preparing ChemoPredict™ for clinical use, ensuring it meets rigorous quality and regulatory standards.
Leiden Bio Science Park: Shaping the Future of Health
Companies like VitroScan showcase how collaboration within Leiden Bio Science Park drives progress. Their partnership with Imuno Therapeutics on projects like HITS (High-throughput ImmunoTherapy Screening) demonstrates how proximity to like-minded innovators accelerates advancements in patient care.
As the most dedicated and experienced LSH-science park in the Netherlands, our ecosystem provides the ideal environment for research and entrepreneurship to thrive, fostering connections that translate into real-world solutions for healthcare challenges. Vitroscan's ChemoPredict™ is a perfect example: by bridging the gap between research and clinical application, it brings helping patients closer on a broader scale.
We congratulate VitroScan on this milestone and look forward to seeing their work's impact on global healthcare.
For more information about Vitroscan, visit their website below.
